Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Selenium Sulfide
Therapeutic Area : Ophthalmology
Study Phase : Phase II/ Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Azura Enrolls First Patient in Phase 3 Trial for MGD Treatment AZR-MD-001
Details : AZR-MD-001 is an ophthalmic ointment, applied directly to the meibomian glands. It is under clinical development for the patients with Contact Lens Discomfort & Meibomian Gland Dysfunction.
Brand Name : AZR-MD-001
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 04, 2024
Lead Product(s) : Selenium Sulfide
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II/ Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Selenium Sulfide
Therapeutic Area : Ophthalmology
Study Phase : Phase II/ Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : AZR-MD-001 is an easy-to-use ophthalmic ointment preparation applied directly to the meibomian glands in the lower eyelid. It is under phase 3 clinical development for the patients with Contact Lens Discomfort (CLD) & Meibomian Gland Dysfunction (MGD).
Brand Name : AZR-MD-001
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 18, 2023
Lead Product(s) : Selenium Sulfide
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II/ Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?